- Home
- NNDM vs ERAS Comparison
NNDM vs ERAS Comparison
Compare NNDM & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNDM
- ERAS
- Stock Information
- Founded
- NNDM 2012
- ERAS 2018
- Country
- NNDM Israel
- ERAS United States
- Employees
- NNDM 649
- ERAS N/A
- Industry
- NNDM Electrical Products
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- NNDM Technology
- ERAS Health Care
- Exchange
- NNDM Nasdaq
- ERAS Nasdaq
- Market Cap
- NNDM 334.6M
- ERAS 348.4M
- IPO Year
- NNDM N/A
- ERAS 2021
- Fundamental
- Price
- NNDM $1.58
- ERAS $1.45
- Analyst Decision
- NNDM
- ERAS Strong Buy
- Analyst Count
- NNDM 0
- ERAS 6
- Target Price
- NNDM N/A
- ERAS $4.83
- AVG Volume (30 Days)
- NNDM 1.8M
- ERAS 1.2M
- Earning Date
- NNDM 08-19-2025
- ERAS 08-11-2025
- Dividend Yield
- NNDM N/A
- ERAS N/A
- EPS Growth
- NNDM N/A
- ERAS N/A
- EPS
- NNDM N/A
- ERAS N/A
- Revenue
- NNDM $58,812,000.00
- ERAS N/A
- Revenue This Year
- NNDM N/A
- ERAS N/A
- Revenue Next Year
- NNDM N/A
- ERAS N/A
- P/E Ratio
- NNDM N/A
- ERAS N/A
- Revenue Growth
- NNDM 7.49
- ERAS N/A
- 52 Week Low
- NNDM $1.34
- ERAS $1.01
- 52 Week High
- NNDM $2.74
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- NNDM 54.88
- ERAS 52.19
- Support Level
- NNDM $1.53
- ERAS $1.38
- Resistance Level
- NNDM $1.69
- ERAS $1.58
- Average True Range (ATR)
- NNDM 0.07
- ERAS 0.11
- MACD
- NNDM 0.01
- ERAS 0.01
- Stochastic Oscillator
- NNDM 66.26
- ERAS 64.86
About NNDM Nano Dimension Ltd.
Nano Dimension Ltd provide industrial manufacturing solutions for design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research and academia, along with government organizations.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.